Shares of Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA – Get Rating) have earned an average rating of “Hold” from the nine analysts that are covering the company, Marketbeat.com reports. Three equities research analysts have rated the stock with a hold rating and two have issued a buy rating on the company. The average 12-month price objective among […]
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA – Get Rating)’s stock price reached a new 52-week low during trading on Wednesday . The company traded as low as $22.80 and last traded at $23.75, with a volume of 211387 shares trading hands. The stock had previously closed at $23.80. Analysts Set New Price Targets ENTA has been the […]
StockNews.com initiated coverage on shares of Enanta Pharmaceuticals (NASDAQ:ENTA – Get Rating) in a research note published on Thursday. The firm issued a hold rating on the biotechnology company’s stock. Several other research firms have also recently commented on ENTA. JPMorgan Chase & Co. cut their price target on Enanta Pharmaceuticals from $74.00 to $60.00 […]
Enanta Pharmaceuticals (NASDAQ:ENTA – Get Rating) had its price objective reduced by HC Wainwright from $68.00 to $48.00 in a research note issued to investors on Tuesday morning, The Fly reports. HC Wainwright also issued estimates for Enanta Pharmaceuticals’ Q3 2023 earnings at ($1.86) EPS, Q4 2023 earnings at ($2.56) EPS, FY2023 earnings at ($7.62) […]
Enanta Pharmaceuticals (NASDAQ:ENTA – Get Rating) had its price target trimmed by Royal Bank of Canada from $48.00 to $33.00 in a report released on Tuesday morning, The Fly reports. Other research analysts also recently issued reports about the company. SVB Leerink reissued a market perform rating and issued a $49.00 price objective on shares […]